Follow Binomial lab on F6S
Symbol:KSR2
Name:kinase suppressor of ras 2
Synonyms: FLJ25965
NCBI Gene:283455
UniProtKB Swiss-Prot: Q6VAB6
Nevi and Melanomas
Nevi and Melanomas
Nevi and Melanomas
Adenoma and adenomacarcinomas
Squamous Cell Neoplasms
F648S
E670K
L671H
G673E
G675D
F677S
R684C
Nevi and Melanomas
Gliomas, Epithelial Neoplasms, NOS
Gliomas
Nevi and Melanomas
D699N
E691D
R692W
E720D
Adenomas and Adenocarcinomas
Cystic, Mucinous and Serous Neoplasms
Epithelial Neoplasms, NOS
S702R
S731R
G744R
R818W
Ductal and lobular neoplasms
Nevi and Melanomas
Adenomas and Adenocarcinomas
Ductal and Lobular Neoplasms
Gliomas

1
1/0
1
1
1
1
1
2
1
1
2
2
2/0
0/2
1
1/1
0/1
1/0
1
1
Mutations of KSR2 have no effect on cellular localisation of KSR2, but many disrupt MAPK/ERK signalling.
Most variants were found in heterozygous form, although one severely obese individual was homozygous for two KSR2 variants (R253W and D323E).
Focused on variants that disrupt (frame-shift/nonsense) or are likely to disrupt (missense mutations in or very close to) the highly conserved kinase domain of KSR2.
Mirdametinib [PD0325901]
is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2
Made on
Tilda